J&J will buy all of Intra-Cellular's shares for $132 apiece, representing a 39% premium to their Friday closing price. Shares ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

JOHNSON & Johnson (J&J) is in talks to acquire Intra-Cellular Therapies ... medical device maker Stryker agreed to buy Inari Medical for about US$4.9 billion. J&J is going back on the offence after ...

To acquire Intra-Cellular Therapies, J&J will buy all outstanding shares of the company for $132 per share through a combination of cash on hand and debt. The transaction is expected to close later ...

J&J said it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into ...

Johnson & Johnson (J&J) is in talks to acquire Intra-Cellular ... agreed to buy Inari Medical Inc. for about $4.9 billion. J&J is going back on the offense after spinning off its consumer health ...

Apple Watch Ultra 2 (GPS+Cellular) is on sale at Best Buy for $739. This is $60 off its list price of $799. An Apple Watch ...

(Reuters) - Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for ... after the company spun off its consumer health unit in 2023.

J&J has offered to buy each share of Intra-Cellular for $132, representing a 39% premium to the stock's closing price on Friday. Shares of Intra-Cellular rose 34% to $128 in afternoon trading ...

Johnson & Johnson on Monday said it has agreed to acquire Intra-Cellular Therapies, a developer of drugs for diseases of the brain, for $132 per share, or about $14.6 billion. The announcement of ...

(RTTNews) - Johnson & Johnson (JNJ) and Intra-Cellular Therapies, Inc. (ITCI) announced Monday that they have entered into a definitive agreement under which Johnson & Johnson will acquire all ...